ArticleOphthalmology and therapy2025
Symptomology and Impact of Dry Eye Disease: A Patient and Physician Perspective.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of stem cell therapy for dry eye syndrome in Sjögren's syndrome: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- The Impact of a Smartphone Reminder Application on Artificial Tear Adherence in Dry Eye Disease.Journal of clinical medicine · 2026Article
- Redefining Dry Eye Disease Management: Emerging Pharmacologic and Device-Based Therapies in the Era of Precision Care: A Narrative Review.Ophthalmology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is a common ocular surface disease that results from tear instability, leading to visual disturbance, decreased work productivity, and reduced quality of life. Contributing factors to DED are multifactorial, ranging from air quality to Sjögren's syndrome (primary or secondary), and the associated comorbidities make management particularly challenging. Additionally, knowledge on the natural history of dry eye is lacking, and there is no consensus on the optimal treatment for various DED subtypes and their comorbidities. It is critical that information remains accurate and accessible to patients, caregivers, and physicians. Here, the experiences of a patient with DED are contextualized by an ophthalmologist with a review of the current available literature on DED to establish a groundwork for future research into DED. The patient experience suggests that a clear and accessible information source for patients and caregivers remains an overlooked aspect of holistic care in DED. Symptoms such as watery eyes and refractive changes are often not well understood by patients, and a systems-based approach suggests that patient care would benefit from multidisciplinary collaborations between ophthalmologists, general physicians, and other health professionals in managing this chronic condition. Further advancements in DED research and delivery of care will depend on increasing community engagement on DED diagnosis, comorbidities, and current evidence-based treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.